FDA Gives Novartis Approval for First-Ever Therapy for NSCLC Tumors with METex14

Trials showed an overall response rate of 68% in treatment naïve patients, and 41% in previously-treated METex14 patients. This oral MET inhibitor is expected to become available to patients in the coming days.